- 专利标题： Methods of reducing symptoms of the ingestion of drugs such as cannabis or 5ht2 agonists via applications with 5ht1/2, CB1, GLP-1 allosteric modulators where the method of delivery/formulation selected from: Inhaler, nebulizer, intravenously, intramuscularly, injection, capsules, tablets, pills.
-
申请号： US18625187申请日： 2024-04-02
-
公开(公告)号： US20240325343A1公开(公告)日： 2024-10-03
- 发明人: david alan heldreth, JR.
- 申请人： david alan heldreth, JR.
- 申请人地址： US WA bellevue
- 专利权人： david alan heldreth, JR.
- 当前专利权人： david alan heldreth, JR.
- 当前专利权人地址： US WA bellevue
- 分案原申请号： US17667147 2022.02.08
- 主分类号： A61K31/352
- IPC分类号： A61K31/352 ; A61K31/015 ; A61K31/05 ; A61K31/135 ; A61K31/164 ; A61K31/165 ; A61K31/404 ; A61K31/4045 ; A61K31/473 ; A61K31/4741 ; A61K31/48 ; A61K31/675 ; A61K31/704 ; A61K33/06 ; A61K33/30 ; A61K36/68 ; A61K36/77
摘要：
The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1 and GLP-1 serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7 and other receptors, in combination with vaccines/antibodies, and phenethylamines, tryptamines, ibogaloids and other compounds; to treat or reduce symptoms of ingestion of drugs such as cannabis or 5-ht2a agonists. The method of delivery/formulation selected from: Inhaler, nebulizer, intravenously, intramuscularly, injection, capsules, tablets, pills.
信息查询
